How should methenamine hippurate be used for prophylaxis of recurrent uncomplicated urinary tract infections in patients with normal renal function who can maintain acidic urine?

Methenamine Hippurate for UTI Prophylaxis

Methenamine hippurate 1 gram twice daily is an effective non-antibiotic option for preventing recurrent UTIs in women with normal renal function, and you should offer it as an alternative to continuous antibiotic prophylaxis. 1, 2

Dosing and Administration

The standard regimen is 1 gram twice daily (morning and night) for adults and patients over 12 years of age 3. This dosing was validated in the landmark ALTAR trial, which demonstrated non-inferiority to daily antibiotic prophylaxis 4.

When to Use Methenamine Hippurate

Offer methenamine hippurate to women with recurrent UTIs (≥3 UTIs per year or ≥2 in 6 months) who:

• Have normal renal function
• Have no structural urinary tract abnormalities 2
• Prefer non-antibiotic prophylaxis
• Are intolerant to or wish to avoid long-term antibiotics
• Have concerns about antimicrobial resistance

The 2025 AUA/CUA/SUFU guidelines provide a Conditional Recommendation (Grade C evidence) 1, while the 2024 EAU guidelines give a Strong Recommendation for its use 2.

Clinical Efficacy

The ALTAR trial (N=240) demonstrated that methenamine hippurate reduced UTI incidence to 1.38 episodes per person-year compared to 0.89 with antibiotics—an absolute difference of 0.49 episodes that did not exceed the predefined non-inferiority margin of 1 UTI per person-year 4. A 2025 meta-analysis confirmed non-inferiority with no significant difference in symptomatic UTI rates (RR 1.15; 95% CI 0.96-1.38) 5.

Importantly, methenamine hippurate substantially reduces UTI recurrence from baseline rates (typically 3-6 episodes per year) to approximately 1.4 episodes per year during treatment 4.

Antimicrobial Resistance Considerations

A critical advantage: methenamine hippurate reduces antibiotic resistance development. During treatment, 72% of women on daily antibiotics developed resistant E. coli versus 56% on methenamine hippurate (p=0.05) 4. However, be aware that post-treatment, 20% of methenamine users showed multidrug resistance versus 5% on antibiotics (p=0.06) 4.

Recent research identified formaldehyde-resistant E. coli strains (5.8% of isolates) with mutations in the frmR gene, suggesting that like antibiotics, methenamine has its own resistance mechanisms 6.

Urine Acidification: The Critical Caveat

You do NOT need to routinely prescribe vitamin C or other urine acidifiers with methenamine hippurate. The 2025 AUA/CUA/SUFU guidelines explicitly state that urinary acidifiers have not been found to significantly lower urinary pH and do not enhance methenamine's effects in RCTs, making concomitant vitamin C use unnecessary 1.

The FDA label suggests that "if necessary, as indicated by urinary pH and clinical response, supplemental acidification should be instituted" 3, but this is not routinely required. Methenamine converts to formaldehyde at acidic pH (optimal at pH 5.6-6.0), and formaldehyde was detected in 85% of ALTAR participant urines without routine acidification 6, 7.

Practical approach: Advise patients to avoid excessive alkalinizing foods/medications, but routine pH monitoring or vitamin C supplementation is not necessary for most patients.

Safety Profile

Methenamine hippurate demonstrates excellent tolerability with adverse event rates similar to antibiotics (RR 0.98; 95% CI 0.86-1.12) 5. The ALTAR trial found comparable adverse events between groups 4. A 2026 study showed significantly fewer adverse events with methenamine versus nitrofurantoin (p<0.05) 8.

Cost-Effectiveness

Despite higher drug acquisition costs, methenamine hippurate results in lower total management costs due to fewer UTI episodes and complications 8. The ALTAR trial found methenamine was less costly and more effective in quality-adjusted life-years, though long-term extrapolation showed variable results 4.

Monitoring and Follow-Up

• Monitor efficacy through repeated urine cultures 3
• Assess clinical response at 3,6, and 12 months
• If breakthrough UTIs occur, consider switching to antibiotic prophylaxis or alternative strategies
• Post-treatment UTI rates may increase (1.72 episodes/year after stopping methenamine vs 1.19 after stopping antibiotics) 4

Position in Treatment Algorithm

Use methenamine hippurate after:

1. Behavioral modifications (increased fluid intake if <1.5L/day) 1
2. Vaginal estrogen (if postmenopausal) 2
3. Consideration of cranberry products (36mg PACs) 1

Use methenamine hippurate before:

• Continuous antibiotic prophylaxis 1, 2
• More invasive interventions like intravesical instillations 2

Key Pitfalls to Avoid

• Don't use in patients with urinary tract abnormalities—efficacy is established only in women without structural abnormalities 2
• Don't routinely prescribe vitamin C—it's unnecessary and not evidence-based 1
• Don't expect complete UTI prevention—methenamine reduces but doesn't eliminate recurrences
• Don't assume it's resistance-free—formaldehyde resistance mechanisms exist 6
• Don't use for acute treatment—methenamine is for prophylaxis only after infection eradication 3